If you have non-small cell lung cancer and your tumor tests positive for the PD-L1 biomarker, you have PD-L1+ (PD-L1 positive) lung cancer. This fact sheet explains what this means and how it may affect lung cancer treatment.

**WHAT IS PD-L1?**

PD-L1 (programmed cell death ligand 1) is a protein that plays a role in the body’s immune system. It can bind to another protein called PD-1. When this happens, the two proteins block the immune system from killing cancer cells. Doctors have figured out how to prevent the two proteins from binding and help the immune system do its job.

**WHAT DO THE RESULTS OF A PD-L1 TEST MEAN?**

A test for PD-L1 will show the level of PD-L1 found in tumor cells. The result will be a percentage. This number reflects the percent of cells in the tumor with PD-L1. Doctors refer to this as PD-L1 expression. A tumor with a higher PD-L1 level may be more likely to respond to PD-L1 treatment. A high level also may be called “PD-L1 positive.”

**RESULTS FOR PD-L1 TESTS COME BACK FROM THE LAB QUICKLY**

PD-L1 tests are easier to run than other biomarker tests recommended for non-small cell lung cancer (NSCLC). Patients with NSCLC who test ALK+ or EGFR+ should get that targeted therapy before they get immunotherapy. Because of this, it is important for you and your oncology care team to wait until all your biomarker results return before starting treatment. This may delay your treatment for a few weeks. But it will ensure that you get the best treatment for you in the right order.
HOW DO DOCTORS TREAT PD-L1+ LUNG CANCERS?

Doctors decide whether to treat lung cancers with PD-L1 drugs based on the level of PD-L1 in the tumor. They also may look at what other treatment options are available. Drugs that treat PD-L1+ cancers are immunotherapy drugs. Immunotherapy works by allowing your own immune system to fight cancer better. The immunotherapy drugs for cancers that are high in PD-L1 are called checkpoint inhibitors. They block PD1 and PD-L1 from binding. This allows the immune system to kill more cancer cells.

The U.S. Food and Drug Administration has approved the drugs listed below for cancers that are PD-L1+. Some are used even when PD-L1 levels are very low. They are given through a vein. All may be used to treat advanced non-small cell lung cancer. Tecentriq, Opdivo, and Keytruda are also used against advanced small cell lung cancer (SCLC). These drugs may be combined with other treatments. If the first drug you try does not work or stops working, ask your doctor about trying another. Clinical trials continue to test more and better ways to use these drugs to treat lung cancer.

✔ Atezolizumab (Tecentriq®)
✔ Durvalumab (Imfinzi®)
✔ Nivolumab (Opdivo®)
✔ Pembrozulimab (Keytruda®)

The following are common side effects of these drugs. **It is very important to report new side effects and changes in side effects to your health care team right away. Most side effects can be managed if they are treated early.** In rare cases, they may lead to more serious conditions.

- Constipation
- Cough
- Diarrhea
- Fatigue
- Flu-like symptoms (chills, fever, headache, nausea)
- Loss of appetite
- Low blood pressure
- Pain or soreness
- Rashes, redness, or itching

**Rare but serious side effects may include:**

- Hepatitis
- Colitis
- Swelling in the lungs
- Severe infections
- Severe skin problems
- Problems in the kidneys, hormone glands, or other organs


PD-L1+ Lung Cancer and Biomarker Testing Information

- **Frankly Speaking About Cancer Targeted Therapy and Biomarker Testing for Lung Cancer** booklet • download or order from [orders.CancerSupportCommunity.org](http://orders.CancerSupportCommunity.org)
- **Frankly Speaking About Cancer Lung Cancer** book • download or order from [orders.CancerSupportCommunity.org](http://orders.CancerSupportCommunity.org)
- **GO2 Foundation for Lung Cancer** • 800-298-2436 • [www.go2foundation.org/lungmatch](http://www.go2foundation.org/lungmatch)
- **LUNGevity Foundation** • 844-360-5864 • [www.LUNGevity.org/biomarkertesting](http://www.LUNGevity.org/biomarkertesting)
Lung Cancer Information, Survivorship, and Support

Cancer Support Community • 888-793-9355 • www.CancerSupportCommunity.org
American Cancer Society • 800-227-2345 • www.cancer.org
American Lung Association • 800-586-4872 • www.lung.org
CancerCare • 800-813-4673 • www.cancercare.org
Cancer.net • 888-651-3038 • www.cancer.net
GO2 Foundation for Lung Cancer • 800-298-2436 • www.go2foundation.org
Lung Cancer Research Foundation • 844-835-4325 • www.lcrf.org
LUNGevity Foundation • 321-407-6100 • www.LUNGevity.org
National Cancer Institute (NCI) • 800-422-6237 • www.cancer.gov
NCI Clinical Trial Information • 800-422-6237 • www.cancer.gov/ClinicalTrials
Patient Advocate Foundation • 800-532-5274 • www.patientadvocate.org

Cancer Support Community Resources

Cancer Support Helpline® — Have questions, concerns or looking for resources? Call CSC’s toll-free Cancer Support Helpline (888-793-9355), available in 200 languages Mon - Fri 9am - 9pm ET.

Open to Options® — Need help making a cancer treatment decision? Our trained specialists can help you create a list of questions to share with your doctor. Make an appointment by calling 888-793-9355 or by contacting your local CSC or Gilda’s Club.

Frankly Speaking About Cancer® — Trusted information for cancer patients and their loved ones is available through publications, online, and in-person programs at www.CancerSupportCommunity.org/FranklySpeakingAboutCancer.

Services at Local CSCs and Gilda’s Clubs — With the help of 170 locations, CSC and Gilda’s Club affiliates provide services free of charge to people touched by cancer. Attend support groups, educational sessions, wellness programs, and more at a location near you. www.CancerSupportCommunity.org/FindLocation

Cancer Experience Registry® — Help others by sharing your cancer patient or cancer caregiver experience via survey at www.CancerExperienceRegistry.org

MyLifeLine — CSC’s private, online community allows patients and caregivers to easily connect with friends and family to receive social, emotional, and practical support throughout the cancer journey and beyond. Sign up at www.MyLifeLine.org.

Grassroots Network — Make sure your voice is heard by federal and state policy makers on issues affecting cancer patients and survivors by joining our Network at www.CancerSupportCommunity.org/become-advocate.

LUNG BIOMARKER DIGITAL TOOL PROGRAM PARTNER:

AMPGene
Association for Molecular Pathology

THIS PROGRAM WAS MADE POSSIBLE THROUGH A CHARITABLE GRANT FROM:

AMGEN Oncology

The Cancer Support Community and its partners provide this information as a service. This publication is not intended to take the place of medical care or the advice of your doctor. We strongly suggest consulting your doctor or other health care professionals to answer questions and learn more.

This booklet is available to download and print at www.CancerSupportCommunity.org/immunotherapy. For print copies of this more resources about coping with cancer, visit Orders.CancerSupportCommunity.org.

© October 2020 Cancer Support Community. All rights reserved.